

CENTOGENE

THE RARE DISEASE COMPANY

Diagnose.
Understand.
Treat.

Baird 2021 Global Healthcare Conference
CENTOGENE (CNTG) Company Presentation
September 14, 2021



Safe Harbor Statement

This presentation has been prepared by Centogene N.V. (The "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains "forward-looking statements" within the meaning of the U.S. Federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continue," "expect," "estimate," "intend," "project" and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, see the Company's risk factors set forth in the Company's form 20-F filed on April 15, 2021 with the Securities and Exchange Commission (the "SEC") and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and the company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

Mission

We are a data-driven rare disease company that unlocks the complexities of patients' biology to diagnose, understand, and treat rare diseases.

Our goal is to enable the cure of 100 rare diseases in 10 years.



Focus on rare diseases driven by high unmet medical needs of rare disease patients and strong commercial opportunity.

Rare diseases space transformed by new technologies creating the opportunity **NOW**

AI and big data empowering the analysis of complex datasets



Breakthrough new therapeutic platforms gaining ground

e.g., Gene, RNA, and cell therapy, CRISPR

Multomics tools accelerating the medical revolution



Market for therapies and diagnostics in rare diseases is growing

~**350 Million** people affected by rare genetic diseases, ~90% undiagnosed.

<**5%** of rare diseases have meaningful therapies, ~7,000 hereditary rare diseases identified.

Orphan Drug Market




CENTOGENE uniquely positions to lead the field in Data-Driven Insights Creator in Rare Diseases

Peer Group of Data-driven Insights Companies

		TEMPUS		SEMA4	insitro		
 Focus on rare diseases	✓	✗	✗	✓	✓	✓	✗
 Databank	✓	✓	✓	✓	✓	✓	✓
 Biosamples	✓	✓	✓	✓	✗	✓	✗
 Proprietary data value chain	✓	✓	✓	✓	✓	✓	✓
 Geographical diversity	✓	✗	✓	✗	✗	✗	✗
 Commercial multiomic products	✓	✗	✗	✗	✗	✓	✗

Reflecting internal assessment. Legend: ✓ fully, ✓ partially, ✗ minor/none

CENTOGENE business model and strategic value creation



At the Core: Our Leading Bio/Databank Enables Key Use Cases With Data Breadth & Multiomic Depth



¹ Illustrative graphs. Metrics dependent on exact definition incl. variant classification.

Geographical diversity – Unique Global reach differentiates CENTOGENE



* Country ranking according to number of commercial orders received. Clinical Diagnostics commercial orders received 2012 to April 2021, order status "cancelled" excluded - Map for illustration purposes only.

Deep data differentiates CENTOGENE

Depth of Bio/Databank



Biomaterial & Extracts

Dried Blood Spots cards, Skin cells



Sociodemographic Information

Age, geography




Clinical Information

For Parkinson's: Age of onset, motor and other symptoms, comorbidities, treatment, etc.



Multiomic Data

For Parkinson's: Parkinson's core genes and panel; Whole Genome Sequencing & biomarker data



1. Why it matters: Large % of patients is not properly diagnosed with genetic data alone
2. Opportunity to mine for biomarkers and drug targets
3. Discover hypotheses in patient derived cell samples (iPSC)

Pharma subscribes to our concept of enabling precision medicine

Generate data and insight exemplified in our recent deals

Our unique position ...



Understand the molecular characteristics of Parkinson's disease



Identify patients with frontal temporal dementia mutations



Turning these insights into precision medicine

... led to pharma engagements



ROPAD* Study to genotype up to 12,500 patients with Parkinson's disease globally



EFRONT* Study to determine prevalence of *GRN* in >3,000 frontotemporal dementia patients across Europe



Combining external hit discovery with CENTOGENE's novel disease insights to produce IND enabling therapies

New core management team bringing unique set of experience & complementary networks from leading international life sciences companies



Andrin Oswald, M.D.
Chief Executive Officer

- › Joined in Dec. 2020
- › 20+ years experience in pharma
- › Prior positions include Director of Industry Engagement & Partnerships at the Gates Foundation, various executive roles at Novartis & Glaxo Smith Kline



René Just
Chief Financial Officer

- › Joined in June 2021
- › 20+ years of finance experience
- › Previous experience in listed and PE owned companies in Pharma, IT and services. Most recently CFO and Co-Managing Director at specialty pharma company Riemser, prior to its sale to ESTEVE



Michael Motz, Ph.D.
Chief Commercial Officer

- › Joined in June 2021
- › 25+ years of industry experience in biotech and pharma in executive and BD positions
- › Expert knowledge in drug discovery and development for rare diseases, incl. lysosomal storage diseases
- › Managed large licensing transactions in U.S. and EU



Patrice Denèfle, Ph.D.
Chief Scientific Officer

- › Joined in Aug. 2021
- › 35+ years leadership experience biotech and pharma, from large company to start-up
- › Biotechnology & biotherapeutics, incl. Genetic therapies, Molecular and clinical pharmacology, Translational Research, and Precision Medicine



Maximilian Schmid, M.D.
Chief Commercial Officer

- › Joined in March 2021
- › 20+ years of experience in Europe, U.S., and APAC
- › Prior positions include Global Head of Medical Affairs at Roche Sequencing; and Ariosa Diagnostics
- › Habilitation in prenatal genetics and experience in management consulting



Prof. Dr. Peter Bauer
Chief Genomic Officer


- › Joined 2016, leading expert in rare disease genetics, instrumental in building up Bio/Databank
- › Proven clinical & medical expertise
- › Authored 140+ publications
- › Vice President of the German Society of Neurogenetics
- › Previously headed the Molecular Diagnostic Lab at the University Hospital Tübingen



Q2 2021 Financials - Strong Revenue

Q2 Revenue¹

(€ Millions)



Financial Highlights

- Revenues more than quadrupled in Q2 2021 compared to Q2 2020, driven by growth from COVID-19 testing and the Diagnostics segment
- Diagnostics revenues (excl. COVID) increased 82% compared to Q2 2020
- Pharma revenues decreased YoY from €3.9 million in Q2 2020 to € 2.8 million in Q2 2021
- Commercial COVID-19 testing contributed €42.3 million in revenues in Q2 2021, up from €2.1 million in Q2 2020

¹Core Business includes Clinical Diagnostics and Pharma segments. May include rounding differences.

Investment summary

Clear focus on core rare disease business

Empowering new management team to execute on mission

Return to pre-pandemic sales growth trajectory in core business segments

Tracking Our Mid-Term Progress

- Revenue in Dx and Pharma segment to outgrow the market
- Reach 1 million patients in Bio/Databank
- Grow physician network of active users
- Reach 10 full disease models
- Sign 2-4 strategic partnership deals towards enabling therapy development

Goal of enabling cure of 100 rare diseases in 10 years



THANK YOU FOR YOUR
ATTENTION.

Q&A